Article Menu

Export Article

More by Authors Links

Article Data

  • Views 1107
  • Dowloads 131

Original Research

Open Access

Establishment and characterization of two cell lines (HEC-155, HEC-180) derived from uterine papillary serous adenocarcinoma

  • T. Iida1,*,
  • M. Hamano2
  • N. Yoshida1
  • K. Yonamine1
  • K. Hayashi1
  • K. Kiguchi1
  • B. lshizuka1
  • Y. Nishimura3
  • T. Arai3
  • M. Kawaguchi3
  • H. Hata4
  • J. Watanabe5
  • H. Kuramoto3,4

1Department of Obstetrics and Gynecology, St. Marianna University School of Medicine, Kawasaki, Japan

2Tissue Culture Center, Japan

3Department of Clinical Cytology, Graduate School of Medical Sciences, Kitasato University, Japan

4Department of Obstetrics and Gynecology, Japan

5Department of Pathology, School of Medicine, Sagamihara, Japan

DOI: 10.12892/ejgo200404423 Vol.25,Issue 4,July 2004 pp.423-427

Published: 10 July 2004

*Corresponding Author(s): T. Iida E-mail:

PDF (2.38 MB) View Full-text

Abstract

Uterine papillary serous adenocarcinoma (UPSC) is an uncommon histologic subtype of endometrial cancer that characteristically behaves aggressively with a poor prognosis. We established two novel cell lines derived from UPSC designated HEC-155 and HEC-180. Both cell lines have been growing steadily in monolayer cultures for over ten years. Overexpression of p53, Ki67 and p27 was detected in both cell lines by immunohistochemistry. Using a DNA sequencing technique, a point mutation of p53 was detected in exon 8, codon 286 in HEC-155 and in exon 6, codon 195 in HEC-180. These newly established cell lines should be useful for investigating the characteristics of UPSC.

Keywords

Uterine papillary serous carcinoma (UPSC); Cell line; p53 mutation

Cite and Share

T. Iida,M. Hamano,N. Yoshida,K. Yonamine,K. Hayashi,K. Kiguchi,B. lshizuka,Y. Nishimura,T. Arai,M. Kawaguchi,H. Hata,J. Watanabe,H. Kuramoto. Establishment and characterization of two cell lines (HEC-155, HEC-180) derived from uterine papillary serous adenocarcinoma. European Journal of Gynaecological Oncology. 2004. 25(4);423-427.

URL:

https://www.ejgo.net/articles/10.12892/ejgo200404423

References

[1] Jeffrey J.F., Krepart G.V., Lotocki R.J.: "Papillary serous adenocarcinoma of the endometrium". Obstet. Gynecol., 1986, 67, 670.

[2] Ward B.G., Wright R.G., Free K.: "Papillary cacinomas of the endometrium". Gynecol. Oncol., 1990, 39, 347.

[3] Gitsch G., Friedlander M.L., Wain G.V., Hacker N.F.: "Uterine papillary serous carcinoma". Cancer, 1995, 75 (9), 2239.

[4] Kuramoto H., Hamano M., Imai M.: "HEC-1 cells". Human Cell., 2002, 15 (2), 81.

[5] Seabright M.: "A rapid banding technique for human chromosomes". Lancet, 1971, 2, 971.

[6] Orita M., Suzuki Y., Hayashi K.: "Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction". Genomics, 1989, 5, 874.

[7] GoffB.A., Kato D., Schmidt RA., Ek M., Ferry J.A., Muntz H.G., et al.: "Uterine papillary serous carcinoma : patterns of metastatic spread". Gynecol. Oncol., 1994, 54, 264.

[8] Nordstrom B., Strang P., Lindgren A., Bergstrom R., Tribukait B.: "Endometrial carcinoma: the prognostic impact of papillary serous carcinoma (UPSC) in relation to nuclear grade, DNA ploidy and p53 expression". Anticancer Res., 1996, 16, 899.

[9] Zheng W., Cao P., Zheng M., Kramer E.E., Godwin T.A.: "p53 overexprssion and bcl-2 persistence in endometrial carcinoma : comparison of papillary serous and endometrioid subtypes". Gynecol. Oneal., 1996, 61, 167.

[10] Tashiro H., Isacson C., Levine R., Kurman R.J., Cho K.R., Hedrick L.: ·"·po:,5J3 ge ene mutat10ns are common m utenne serous carcinoma and occur early in their pathogenesis". Am. J. Pathol., 1997, 150 (1), 177.

[11] Hockenbery D.M., Nunez G., Milliman C., Schreiber R.D., Korsmeyer S.J.: "Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death". Nature, 1990, 348, 334.

[12] Ohkouchi T., Sakuragi N., Watari H., Nomura E., Todo Y., Yamada H., Fujimoto S.: "Prognostic significance of Bcl-2, p53 overexpression, and lymphnode metastasis in surgically staged endometrial carcinoma". Am. J. Obstet. Gynecol., 2002, 187 (2), 353.

[13] Polyak K., Kato J.Y., Solomon M.J., Sherr C.J., Massague J., Roberts J.M., Koff A.: "p27Kip l , a cyclyn-Cdk inhibitor, links transforming growth factor-B and contact inhibition to cell cycle arrest". Gene. Dev., 1994, 8, 9.

[14] Shiozawa T., Nikaido T., Nakayama K., Lu X., Fujii S.: "Involvement of cyclin-dependent kinase inhibitor p27Kipl in growth inhibition of endometrium in the secretory phase and of hyperplastic endometrium treated with progesterone". Mo/. Human Reprod., 1998, 4 (9), 899.

[15] Bamberger A.M., Riethdorf L., Milde-Langosch K., Bamberger C.M., Thuneke I., Erdmann I. et al.: "Strongly reduced expression of the cell cycle inhibitor p27 in endometrial neoplasia". Virchows Arch., 1999, 434, 423.

[16] Nycum L.R., Smith L.M., Farley J.H., Kost E.R., Method M.W., Birrer M.J.: "The role of p27 in endometrial carcinoma". Gynecol. Oneal., 2001, 81 (2), 242.

[17] Watanabe J., Sato H., Kanai T., Karnata Y., Jobo T., Hata H. et al.: "Paradoxical expression of cell cycle inhibitor p27 in endometrioid adenocarcinoma of the uterine corpus - correlation with proliferation and clinicopathological parameters". Br. J. Cancer, 2002, 81 (1), 81.

[18] Schmitz M.J., Hendricks D.T., Farley J., Taylor R.R., Geradts J., Rose G.S., Birrer M.J.: "p27 and cyclin Dl abnormalities in uterine papillary serous carcinoma". Gynecol. Oneal., 2000, 77, 439.

Submission Turnaround Time

Top